OVID
Ovid Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.74
+14.17%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.50
From 52W high−7.43%
Volume3.58M
Market cap$535.12M
P/E (TTM)—
P/S (TTM)338.0x
Div yield—
Key dataNov 4, 2026
Open
$2.50
From 52W high
−7.43%
Volume
3.58M
Market cap
$535.12M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.1x
P/E (TTM)
—
RSI (14)
50.8
MomentumView details →
1D Return
+14.17%
YTD Return
+48.39%
SummaryUpdated Jun 1, 2026
Ovid Therapeutics Inc. (NASDAQ:OVID) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in New York, New York. The company went public in May 2017 and focuses exclusively on developing treatments for rare neurological disorders that primarily affect children and families. Ovid operates as a specialized biotech firm targeting underserved patient populations with significant unmet medical needs, particularly in conditions like fragile X syndrome, tuberous sclerosis complex, and Angelman syndrome.
Similar companies
Latest newsMore news →
Ovid Therapeutics Inc. reported its financial results for the second quarter ended June 30, 2026.84d agoOvid Therapeutics appointed Kevin Norrett as Chief Business Officer and promoted its CFO and Chief Strategy Officer.120d agoJeffrey Rona departed as Chief Business and Financial Officer of Ovid Therapeutics Inc. effective July 6, 2026, and Charles Carter was promoted to Chief Financial Officer, principal financial officer, principal accounting officer and secretary, effective the same date.120d ago